Abstract
A clinical decision report appraising: Schwartz CL, Wexler LH, Krailo MD, et al. Intensified chemotherapy with dexrazoxane cardioprotection in newly diagnosed nonmetastatic osteosarcoma: A report from the Children’s Oncology Group. Pediatr Blood Cancer. 2016;63(1):54-615. https://doi.org/10.1002/pbc.25753 for a patient with osteosarcoma and concerns about the risk of secondary malignant neoplasms that attend use of dexarazoxane.
Highlights
Follow this and additional works at: https://digitalcommons.wayne.edu/crp Part of the Cardiology Commons, Medical Education Commons, Medical Pharmacology Commons, and the Oncology Commons
Dexrazoxane decreases the cardiotoxic effects of doxorubicin in osteosarcoma patients without increasing mortality from secondary malignant neoplasms
Kopp et al conducted a retrospective study of 2 cohorts assessing dexrazoxane cardioprotection and secondary malignant neoplasms (SMN) in patients with osteosarcoma who were being treated with doxorubicin or trastuzumab
Summary
Schwartz CL, Wexler LH, Krailo MD, et al Intensified chemotherapy with dexrazoxane cardioprotection in newly diagnosed nonmetastatic osteosarcoma: A report from the Children’s Oncology Group. Pediatr Blood Cancer. 2016;63(1):54-615. https://doi.org/10.1002/pbc.25753
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
